Head-To-Head Analysis: Aspira Women’s Health (AWH) vs. The Competition

Aspira Women’s Health (NASDAQ: AWH) is one of 35 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Aspira Women’s Health to related companies based on the strength of its analyst recommendations, risk, earnings, institutional ownership, profitability, valuation and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Aspira Women’s Health and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aspira Women’s Health 0 1 2 0 2.67
Aspira Women’s Health Competitors 351 877 1105 104 2.39

As a group, “Diagnostic substances” companies have a potential downside of 12.01%. Given Aspira Women’s Health’s competitors higher possible upside, analysts clearly believe Aspira Women’s Health has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Aspira Women’s Health and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Aspira Women’s Health $4.54 million -$15.24 million -24.50
Aspira Women’s Health Competitors $296.42 million -$15.37 million 111.39

Aspira Women’s Health’s competitors have higher revenue, but lower earnings than Aspira Women’s Health. Aspira Women’s Health is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

22.9% of Aspira Women’s Health shares are held by institutional investors. Comparatively, 48.2% of shares of all “Diagnostic substances” companies are held by institutional investors. 4.7% of Aspira Women’s Health shares are held by insiders. Comparatively, 8.7% of shares of all “Diagnostic substances” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Aspira Women’s Health has a beta of 3.31, meaning that its share price is 231% more volatile than the S&P 500. Comparatively, Aspira Women’s Health’s competitors have a beta of 1.67, meaning that their average share price is 67% more volatile than the S&P 500.

Profitability

This table compares Aspira Women’s Health and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aspira Women’s Health -323.40% -177.99% -109.61%
Aspira Women’s Health Competitors -992.97% -556.43% -52.70%

Summary

Aspira Women’s Health competitors beat Aspira Women’s Health on 7 of the 13 factors compared.

About Aspira Women’s Health

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company provides sells OVA1, Overa, and Ova1PLUS risk of malignancy tests for ovarian cancer. It also offers ASPiRA GenetiX, a genetic test for specific women's health diseases. In addition, the company owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, it is developing diagnostic algorithms, as well as a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. The company serves physicians, physician office laboratories, and hospital laboratories. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was founded in 1993 and is headquartered in Austin, Texas.

Receive News & Ratings for Aspira Women's Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspira Women's Health and related companies with MarketBeat.com's FREE daily email newsletter.

Head-To-Head Analysis: Aspira Women’s Health (AWH) vs. The Competition

Aspira Women’s Health (NASDAQ: AWH) is one of 35 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Aspira Women’s Health to related companies based on the strength of its analyst recommendations, risk, earnings, institutional ownership, profitability, valuation and dividends.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Aspira Women’s Health and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aspira Women’s Health 0 1 2 0 2.67
Aspira Women’s Health Competitors 351 877 1105 104 2.39

As a group, “Diagnostic substances” companies have a potential downside of 12.01%. Given Aspira Women’s Health’s competitors higher possible upside, analysts clearly believe Aspira Women’s Health has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Aspira Women’s Health and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Aspira Women’s Health $4.54 million -$15.24 million -24.50
Aspira Women’s Health Competitors $296.42 million -$15.37 million 111.39

Aspira Women’s Health’s competitors have higher revenue, but lower earnings than Aspira Women’s Health. Aspira Women’s Health is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

22.9% of Aspira Women’s Health shares are held by institutional investors. Comparatively, 48.2% of shares of all “Diagnostic substances” companies are held by institutional investors. 4.7% of Aspira Women’s Health shares are held by insiders. Comparatively, 8.7% of shares of all “Diagnostic substances” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Aspira Women’s Health has a beta of 3.31, meaning that its share price is 231% more volatile than the S&P 500. Comparatively, Aspira Women’s Health’s competitors have a beta of 1.67, meaning that their average share price is 67% more volatile than the S&P 500.

Profitability

This table compares Aspira Women’s Health and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aspira Women’s Health -323.40% -177.99% -109.61%
Aspira Women’s Health Competitors -992.97% -556.43% -52.70%

Summary

Aspira Women’s Health competitors beat Aspira Women’s Health on 7 of the 13 factors compared.

About Aspira Women’s Health

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company provides sells OVA1, Overa, and Ova1PLUS risk of malignancy tests for ovarian cancer. It also offers ASPiRA GenetiX, a genetic test for specific women's health diseases. In addition, the company owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, it is developing diagnostic algorithms, as well as a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. The company serves physicians, physician office laboratories, and hospital laboratories. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was founded in 1993 and is headquartered in Austin, Texas.

Receive News & Ratings for Aspira Women's Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspira Women's Health and related companies with MarketBeat.com's FREE daily email newsletter.